Consistently, in the CSF of MS patients, IL-9 levels inversely correlate with neurofilament levels, a marker of neurodegeneration, as well as with levels of IL-17, which are indicative of neuroinflammation [119]. Here, IL17A is linked to myeloid sarcoma.